Fact Sheet: President Donald J. Trump Announces Deal with Regeneron to Bring Most-Favored-Nation Pricing to American Patients

President Donald J. Trump has announced a landmark agreement with Regeneron, marking the 17th and final deal with the nation’s leading pharmaceutical manufacturers to implement Most-Favored-Nation (MFN) pricing. With this agreement, the administration now has commitments from companies representing 86% of the branded drug market to ensure American patients pay the same low prices for innovative drugs as other developed nations.The announcement follows the administration's broader strategy to end foreign "freeriding" on American innovation and lower out-of-pocket costs through the TrumpRx platform.Massive Price Reductions: Through the TrumpRx.gov platform, the price of Regeneron’s cholesterol medication, Praluent, will be slashed from No-Cost Gene Therapy: In a major breakthrough, Regeneron’s new gene therapy for genetic deafness, Otarmeni, will be provided to American patients at no cost. The drug was approved on an accelerated timeline via the FDA’s new National Priority Voucher Program.Medicaid Savings: All state Medicaid programs will now have access to MFN pricing for Regeneron products, a move expected to save taxpayers hundreds of millions of dollars.Revenue Repatriation: Under the "America First" trade policy, Regeneron is required to repatriate increased foreign revenue to benefit American patients.Regeneron has committed to a The administration’s push to rebalance global drug pricing has moved rapidly since 2025:May 2025: President Trump signed the "Delivering MFN Prescription Drug Pricing" Executive Order.December 2025: An agreement was reached with the United Kingdom, increasing the price of drugs in the U.K. by 25% to ensure they pay a fair share for R&D.February 2026: TrumpRx.gov was launched as a direct-to-consumer portal for MFN-priced medicines.With the addition of Regeneron, the President has secured MFN agreements with the following 17 global leaders:PfizerAstraZenecaEli LillyNovo NordiskAmgenBristol Myers SquibbJohnson & JohnsonAbbVieMerckNovartisSanofiRegeneron(And five others: EMD Serono, Boehringer Ingelheim, Genentech, Gilead Sciences, and GSK)